New tests launched in January


New Tests

In January 2022, Mayo Clinic Laboratories announced twenty five new tests along with numerous reference value changes, obsolete tests, and algorithm changes.

The new tests that launched in January 2022 by Mayo Clinic Laboratories:

T821Q | RUNX1-RUNX1T1 Translocation (8;21), Minimal Residual Disease Monitoring, Quantitative, Varies

This test is intended for detection of RUNX1-RUNX1T1 gene fusion in acute myeloid leukemia (AML) patients at the time of diagnosis.

Minimal residual disease (MRD) monitoring during the clinical and therapeutic course of these patients.

BARTB | Bartonella, Molecular Detection, PCR, Blood

This test is intended for aiding in the diagnosis of Bartonella infection when Bartonella DNA would be expected to be present in blood, especially endocarditis.

BARRP | Bartonella, Molecular Detection, PCR, Varies

This test is intended for aiding in the diagnosis of Bartonella infection

AFH | Factor H Autoantibody, Serum

This test is intended for detecting and quantification of antibodies to factor H. Monitoring patients with known factor H autoantibodies. Aiding in the differential diagnosis of thrombotic microangiopathy and C3 glomerulopathies.

FBL | Fungal Culture, Blood

This test is intended for diagnosis and treatment of the etiologic agents of fungemia. Select patient population that presents with signs and symptoms of sepsis, especially fever of unknown origin.

MBLF | Mannan Binding Lectin Complement Pathway, Functional, Serum

This test is intended for investigation of recurrent meningococcal disease in young children. Investigation of recurrent or severe infections in adults. Investigation of glomerular kidney diseases.

Additionally, deficiencies or dysregulation within the complement system may be identified in patients when this test is used in combination with related tests.

HPVHR | Human Papillomavirus (HPV), High-Risk, DNA In Situ Hybridization

This test is intended for detection of human papillomavirus DNA from high-risk genotypes (16, 18, 31, 33, and 51).

RSVQL | Respiratory Syncytial Virus, RNA, Qualitative Detection, Varies

This test is intended for detection of respiratory syncytial virus (RSV) in upper or lower respiratory tract specimens from individuals at risk for RSV infection with flu-like illness.

SCOFR | Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) RNA, Influenza Virus Type A and Type B RNA, and Respiratory Syncytial Virus (RSV) RNA Detection by PCR, Varies

This test is intended for simultaneous detection and differentiation of coronavirus disease 2019 (COVID-19) (due to severe acute respiratory syndrome coronavirus 2: SARS-CoV-2), influenza A, influenza B, and respiratory syncytial viral infection in a single upper respiratory tract specimen from an individual with flu-like illness.

MNCU | Manganese/Creatinine Ratio, Urine

This test is intended for measurement of manganese as a part of a profile, monitoring manganese exposure, nutritional monitoring, and clinical trials.

MNRCU | Manganese/Creatinine Ratio, Random, Urine

This test is intended for monitoring manganese exposure using random urine specimens, nutritional monitoring, and clinical trials.

LHSV | Herpes Simplex Virus (HSV), Molecular Detection, PCR, Varies

This test is intended for aiding in the rapid diagnosis of herpes simplex virus (HSV) infections, including qualitative detection of HSV DNA in nonblood clinical specimens.

This test should not be used to screen asymptomatic patients.

LHSVB | Herpes Simplex Virus (HSV), Molecular Detection, PCR, Blood

This test in intended for qualitative detection of HSV DNA.

This test should not be used to screen asymptomatic patients.

HBGSN | Hepatitis B Surface Antigen Screen, Serum

This test is intended for diagnosis of acute, recent, or chronic hepatitis B infection.

Determination of chronic hepatitis B infection status.

This test is not offered as a screening or confirmatory test for blood donor specimens.

This test, by itself, is not useful during the "window period" of acute hepatitis B virus (HBV) infection (ie, after disappearance of hepatitis B surface antigen and prior to appearance of hepatitis B surface antibody). Testing for acute HBV infection should also include hepatitis B core IgM antibody (anti-HBc IgM).

HBCSN | Hepatitis B Core Total Antibodies Screen, Serum

This test is intended for diagnosis of recent or past hepatitis B infection.

Determination of occult hepatitis B infection in otherwise healthy hepatitis B virus (HBV) carriers with negative test results for hepatitis B surface antigen, anti-hepatitis B surface, anti-hepatitis B core IgM, hepatitis Be antigen, and anti-HBe.

This assay is not useful for differentiating among acute, chronic, and past or resolved hepatitis B infection.

This test is not offered as a screening or confirmatory test for blood donor specimens.

CHBVS | Chronic Hepatitis B Screen, Serum

This test is intended for diagnosis and evaluation of patients at risk for or suspected of having chronic hepatitis B.

This test is not offered as a screening or confirmatory test for blood donor specimens.

This test is not useful during "window period" of acute hepatitis B virus infection (ie, after disappearance of hepatitis B surface antigen [HBsAg] and prior to appearance of hepatitis B surface antibody).

This test is not useful as a stand-alone prenatal screening test of HBsAg status in pregnant women.

HBPES | Hepatitis B Virus Past Exposure Panel, Serum

This test is intended for screening for past exposure to hepatitis B virus (HBV).

Determining HBV infection status prior to initiating chemotherapy or other immunosuppressive therapies.

HBBSN | Hepatitis B Surface Antibody Screen, Qualitative/Quantitative, Serum

This test is intended for identifying previous exposure to hepatitis B virus.

HBCPR | Hepatitis B Core Total Antibodies Prenatal, Serum

This test is intended for diagnosis of recent or past hepatitis B infection in pregnant individuals.

Determination of occult hepatitis B infection in otherwise healthy hepatitis B virus (HBV) carriers with negative test results for hepatitis B surface antigen, anti-hepatitis B surface, anti-hepatitis B core IgM, hepatitis Be antigen, and anti-HBe.

This assay is not useful for differentiating among acute, chronic, and past or resolved hepatitis B infection.

This test is not offered as a screening or confirmatory test for blood donor specimens.

HBABP | Hepatitis B Surface Antibody Prenatal, Qualitative/Quantitative, Serum

This test is intended for identifying previous exposure to hepatitis B virus in pregnant individuals.

Determining adequate immunity from hepatitis B vaccination.

NSYPH | Syphilis IgG Enzyme Immunoassay, Serum

This test is intended for an aid in the diagnosis of infection with Treponema pallidum.

Routine prenatal screening.

This test is not useful for diagnosis of congenital syphilis.

This test is not offered as a screening or confirmatory test for blood donor specimens.

GDUCR | Gadolinium/Creatinine Ratio, Random, Urine

This test is intended for assessing chronic exposure and monitoring effectiveness of dialysis in a random urine collection.

HIAAR | 5-Hydroxyindoleacetic Acid, Random, Urine

This test is intended for biochemical diagnosis and monitoring of intestinal carcinoid syndrome using random urine specimens.

RRPRS | Rapid Plasma Reagin Screen with Reflex to Titer, Serum

This test is intended for aiding in the diagnosis of recent or past Treponema pallidum infection.

Rapid plasma reagin screening when T pallidum antibody screen is positive.

This test is not useful as a screening or confirmatory test for blood donor specimens.

SYPH1 | Syphilis IgG with Reflex, Enzyme Immunoassay, Serum

This test is intended for aid for the diagnosis of infection with Treponema pallidum using an algorithmic approach.

Routine prenatal screening.

This test is not offered as a screening or confirmatory test for blood donor specimens.

This test is not useful for diagnosis of congenital syphilis.

In addition to these tests, the department also announced several test changes. Click the links below to view test changes announced by Mayo Clinic Laboratories:

Chantell Canfield (@chantellcanfield)

Chantell Canfield

Chantell Canfield is a web content coordinator for Mayo Clinic Laboratories. She began working for Mayo Clinic in 2021.